Nanobiotix (NBTX) Financials

$46.20 -3.28 (-6.63%)

Closing price 04:00 PM Eastern

Extended Trading

$46.81 +0.61 (+1.32%)

As of 04:10 PM Eastern

Annual Income Statements for Nanobiotix

This table shows Nanobiotix's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-69	-57	-41	-53	-61	-44	-71	-28
Consolidated Net Income / (Loss)	-35	-57	-41	-53	-61	-44	-71	-28
Net Income / (Loss) Continuing Operations	-35	-57	-41	-53	-61	-44	-71	-28
Total Pre-Tax Income	-35	-57	-41	-53	-61	-44	-70	-28
Total Operating Income	-34	-52	-45	-60	-50	-30	-71	-13
Total Gross Profit	3.98	2.85	3.07	3.00	5.11	40	-7.44	38
Total Revenue	3.98	2.85	3.07	3.00	5.11	40	-7.44	38
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	38	55	48	63	55	70	63	51
Selling, General & Admin Expense	14	21	18	22	19	24	21	24
Research & Development Expense	24	34	30	34	35	42	42	27
Other Operating Expenses / (Income)	-	0.00	0.00	6.13	1.05	2.81	0.14	-0.08
Total Other Income / (Expense), net	-0.63	-4.64	3.48	6.32	-11	-14	0.37	-15
Interest Expense	1.66	5.58	-3.23	0.88	15	16	7.75	18
Interest & Investment Income	1.34	0.94	0.25	7.20	3.78	2.21	8.12	2.46
Income Tax Expense	0.00	0.00	0.01	0.01	0.01	0.13	0.10	0.00
Basic Earnings per Share	($1.77)	($2.35)	($1.38)	($1.35)	($1.75)	($1.19)	($1.49)	($0.59)
Weighted Average Basic Shares Outstanding	-	-	34.43M	34.83M	34.88M	47.13M	47.43M	48.41M
Diluted Earnings per Share	($1.77)	($2.35)	($1.38)	($1.35)	($1.75)	($1.19)	($1.49)	($0.59)
Weighted Average Diluted Shares Outstanding	-	-	34.43M	34.83M	34.88M	47.13M	47.43M	48.41M
Weighted Average Basic & Diluted Shares Outstanding	-	-	34.43M	34.83M	34.88M	47.13M	47.43M	48.41M

No quarterly income statements for Nanobiotix are available.

This table details how cash moves in and out of Nanobiotix's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-13	-1.24	103	-40	-46	-43	-26	3.54
Net Cash From Operating Activities	-15	-46	-34	-34	-40	-43	-21	9.07
Net Cash From Continuing Operating Activities	-15	-46	-27	-34	-47	-43	-21	9.07
Net Income / (Loss) Continuing Operations	-35	-57	-41	-53	-61	-44	-71	-28
Consolidated Net Income / (Loss)	-35	-57	-41	-53	-61	-44	-71	-28
Depreciation Expense	0.71	1.98	2.14	1.77	1.60	1.67	1.68	1.75
Non-Cash Adjustments To Reconcile Net Income	22	7.25	6.11	6.15	5.87	-7.58	30	34
Changes in Operating Assets and Liabilities, net	0.72	1.79	5.76	11	6.77	7.29	18	1.80
Net Cash From Investing Activities	-0.48	-1.64	-0.14	-0.27	0.15	0.00	-0.88	-0.63
Net Cash From Continuing Investing Activities	-0.48	-1.64	-0.14	-0.27	0.15	0.00	-0.88	-0.63
Purchase of Property, Plant & Equipment	-	-1.62	-0.12	-0.26	-0.10	-	-0.88	-0.63
Net Cash From Financing Activities	0.00	47	137	-5.86	-6.05	0.00	-3.18	-4.17
Net Cash From Continuing Financing Activities	0.00	45	137	-5.91	-6.04	0.00	-3.18	-4.17
Repayment of Debt	-	-2.15	-2.29	-5.52	-6.04	-	-3.18	-4.17
Effect of Exchange Rate Changes	0.06	-	-	-	-	-	0.10	-0.47
Cash Interest Paid	0.00	-	-	-	-	-	1.01	1.80
Cash Income Taxes Paid	-	-	-	-	-	-	0.06	0.23

No quarterly cash flow statements for Nanobiotix are available.

This table presents Nanobiotix's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	1/1/2019	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	58	63	164	115	64	104	70	80
Total Current Assets	7.15	52	153	105	56	94	64	74
Cash & Equivalents	0.00	39	146	95	44	83	51	62
Accounts Receivable	0.00	0.01	0.08	0.00	0.11	1.00	3.08	2.51
Other Current Assets	7.15	12	7.37	10	12	10	9.06	9.23
Plant, Property, & Equipment, net	9.51	11	10	9.26	7.62	6.91	5.73	5.36
Plant, Property & Equipment, gross	-	11	10	9.26	7.62	6.91	5.73	5.36
Total Noncurrent Assets	0.00	58	0.64	0.59	0.31	46	0.43	0.52
Long-Term Investments	-	-	-	-	-	-	0.42	0.51
Intangible Assets	0.00	57	0.03	0.00	0.00	44	0.01	0.01
Total Liabilities & Shareholders' Equity	35	120	164	115	64	148	70	80
Total Liabilities	35	65	18	33	36	106	138	179
Total Current Liabilities	6.34	16	23	42	41	55	61	67
Accounts Payable	0.00	8.72	8.68	7.34	10	20	21	11
Current Deferred Revenue	-	-	-	0.29	0.06	-	0.06	0.05
Other Current Liabilities	6.34	7.38	8.63	25	25	35	40	57
Total Noncurrent Liabilities	28	49	54	43	52	50	77	111
Other Noncurrent Operating Liabilities	28	49	0.51	0.36	0.29	50	48	107
Total Equity & Noncontrolling Interests	0.00	55	502	84	32	42	-68	-99
Total Preferred & Common Equity	0.00	55	1.26	30	-29	42	2.51	-71
Preferred Stock	-	-	312	289	274	-	324	369
Total Common Equity	0.00	55	189	-206	-242	42	-321	-440
Common Stock	0.00	173	1.26	1.18	1.12	348	1.47	1.70
Treasury Stock	0.00	-0.19	0.24	-0.23	-0.24	-0.25	-0.24	-0.27
Accumulated Other Comprehensive Income / (Loss)	0.00	0.49	0.68	0.73	0.75	0.82	0.74	0.81
Other Equity Adjustments	0.00	-118	187	-208	-243	-306	-323	-442

No quarterly balance sheets for Nanobiotix are available.

This table displays calculated financial ratios and metrics derived from Nanobiotix's official financial filings.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	0.00	68,864,244.00	34,825,872.00	34,875,872.00	47,133,328.00	-	48,410,068.00
DEI Adjusted Shares Outstanding	0.00	0.00	68,864,244.00	34,825,872.00	34,875,872.00	47,133,328.00	-	48,410,068.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	-0.60	-1.53	-1.75	-0.93	-	-0.58
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	-28.38%	7.61%	-2.37%	70.55%	683.90%	-118.58%	613.89%
EBITDA Growth	0.00%	-48.48%	16.15%	-36.32%	16.26%	42.20%	-147.28%	84.17%
EBIT Growth	0.00%	-51.17%	15.23%	-33.72%	16.04%	40.71%	-138.97%	82.07%
NOPAT Growth	0.00%	-52.56%	15.23%	-33.72%	16.04%	40.71%	-138.97%	82.07%
Net Income Growth	0.00%	-64.53%	28.19%	-29.64%	-14.71%	28.03%	-60.59%	60.13%
EPS Growth	0.00%	-32.47%	41.28%	2.17%	-29.96%	31.91%	-24.76%	60.63%
Operating Cash Flow Growth	0.00%	-216.47%	27.19%	-0.50%	-17.40%	-7.14%	-54.75%	142.61%
Free Cash Flow Firm Growth	0.00%	0.00%	77.36%	-80.62%	-8.71%	113.88%	-95.25%	27,920.58%
Invested Capital Growth	0.00%	187.43%	-97.68%	-3,566.03%	-29.86%	-153.52%	-120.19%	-73.09%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	100.00%
EBITDA Margin	-854.41%	-1,771.43%	-1,380.37%	-1,927.43%	-946.44%	-69.78%	0.00%	-28.60%
Operating Margin	-864.24%	-1,840.97%	-1,450.20%	-1,986.36%	-977.85%	-73.96%	0.00%	-33.19%
EBIT Margin	-872.20%	-1,840.97%	-1,450.20%	-1,986.36%	-977.85%	-73.96%	0.00%	-33.19%
Profit (Net Income) Margin	-872.23%	-2,003.74%	-1,337.18%	-1,775.71%	-1,194.33%	-109.65%	0.00%	-73.52%
Tax Burden Percent	99.10%	100.01%	100.02%	100.01%	100.02%	100.30%	100.15%	100.01%
Interest Burden Percent	100.91%	108.84%	92.18%	89.39%	122.12%	147.80%	99.47%	221.47%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-389.96%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-386.30%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	375.21%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-207.79%	-14.75%	-18.18%	-105.57%	-118.75%	539.71%	33.65%
Cash Return on Invested Capital (CROIC)	0.00%	-449.73%	-199.04%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-59.37%	-86.37%	-39.24%	-42.67%	-55.78%	-35.31%	0.00%	-17.01%
Return on Assets (ROA)	-59.37%	-94.00%	-36.18%	-38.15%	-68.13%	-52.34%	0.00%	-37.67%
Return on Common Equity (ROCE)	0.00%	-207.79%	-6.47%	0.52%	408.61%	320.52%	5,768.62%	153.21%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-103.90%	-3,251.69%	-175.45%	210.91%	0.00%	-2,804.94%	0.00%
Net Operating Profit after Tax (NOPAT)	-24	-37	-31	-42	-35	-21	-50	-8.89
NOPAT Margin	-604.97%	-1,288.68%	-1,015.14%	-1,390.45%	-684.49%	-51.77%	0.00%	-23.23%
Net Nonoperating Expense Percent (NNEP)	-59.59%	-71.25%	-3.66%	-3.86%	-36.05%	-35.20%	-39.40%	-47.03%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-108.99%	-49.52%	72.86%	8.96%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	363.70%	744.16%	581.65%	734.19%	373.89%	60.90%	0.00%	62.47%
R&D to Revenue	600.55%	1,196.81%	968.55%	1,147.64%	683.33%	106.05%	0.00%	70.92%
Operating Expenses to Revenue	964.24%	1,940.97%	1,550.20%	2,086.36%	1,077.85%	173.96%	0.00%	133.19%
Earnings before Interest and Taxes (EBIT)	-35	-52	-45	-60	-50	-30	-71	-13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-34	-51	-42	-58	-48	-28	-69	-11
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	1.79	0.64	0.00	0.00	6.06	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.64	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	24.75	34.56	39.25	93.09	25.02	6.34	0.00	28.67
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	3.79	791.86	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	24.75	20.75	93.62	158.02	69.90	4.26	0.00	36.68
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	154.66
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	39.36	1,975.56	24.30
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-1.04	-0.97	-1.02	-1.25	-1.78	4.07	0.49
Leverage Ratio	0.00	2.21	0.41	0.48	1.55	2.27	-6.64	-0.89
Compound Leverage Factor	0.00	2.41	0.38	0.43	1.89	3.35	-6.61	-1.98
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	62.29%	346.60%	852.65%	0.00%	-475.99%	-372.14%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	100.00%	37.71%	-246.60%	-752.65%	100.00%	472.29%	443.78%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-0.16	-1.11	4.13	4.09	-0.08	1.34	-2.82	3.73
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	56.13%	102.87%	487.06%	369.92%	-968.84%	-355.38%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	1.13	3.22	6.58	2.53	1.38	1.71	1.04	1.09
Quick Ratio	0.00	2.45	6.26	2.28	1.09	1.53	0.89	0.95
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-70	-16	-29	-31	4.33	0.21	58
Operating Cash Flow to CapEx	0.00%	-2,851.04%	-28,685.44%	-12,820.62%	-39,895.46%	0.00%	-2,438.89%	1,436.80%
Free Cash Flow to Firm to Interest Expense	0.00	-12.59	0.00	-32.53	-2.11	0.26	0.03	3.23
Operating Cash Flow to Interest Expense	-8.80	-8.28	0.00	-38.30	-2.68	-2.60	-2.76	0.51
Operating Cash Flow Less CapEx to Interest Expense	-8.52	-8.57	0.00	-38.60	-2.68	-2.60	-2.87	0.47
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.07	0.05	0.03	0.02	0.06	0.48	0.00	0.51
Accounts Receivable Turnover	0.00	0.00	69.68	0.00	0.00	72.22	0.00	13.69
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.42	0.28	0.30	0.31	0.61	5.51	0.00	6.90
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	5.24	0.00	0.00	5.05	0.00	26.66
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	5.24	0.00	0.00	5.05	0.00	26.66
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	-18	16	0.36	-13	-16	-41	-91	-158
Invested Capital Turnover	-0.22	-2.54	0.38	-0.49	-0.35	-1.39	0.00	-0.31
Increase / (Decrease) in Invested Capital	0.00	33	-15	-13	-3.76	-25	-50	-67
Enterprise Value (EV)	99	59	287	473	357	171	407	1,403
Market Capitalization	99	99	120	279	128	254	135	1,097
Book Value per Share	$0.00	$7.53	$5.49	($5.98)	($6.93)	$1.20	($6.81)	($9.28)
Tangible Book Value per Share	$0.00	($0.32)	$5.49	($5.98)	($6.93)	($0.06)	($6.82)	($9.28)
Total Capital	0.00	55	502	84	32	42	-68	-99
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-39	-146	-95	-44	-83	-52	-62
Capital Expenditures (CapEx)	-0.48	1.62	0.12	0.26	0.10	0.00	0.88	0.63
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.81	-3.72	-16	-31	-29	-44	-49	-56
Debt-free Net Working Capital (DFNWC)	0.81	36	130	64	15	39	2.62	6.15
Net Working Capital (NWC)	0.81	36	130	64	15	39	2.62	6.15
Net Nonoperating Expense (NNE)	11	20	9.88	12	26	23	21	19
Net Nonoperating Obligations (NNO)	-18	-39	-501	-96	-48	-83	-23	-59
Total Depreciation and Amortization (D&A)	0.71	1.98	2.14	1.77	1.60	1.67	1.68	1.75
Debt-free, Cash-free Net Working Capital to Revenue	20.42%	-130.42%	-515.29%	-1,046.69%	-564.61%	-109.79%	0.00%	-145.76%
Debt-free Net Working Capital to Revenue	20.42%	1,250.69%	4,227.99%	2,123.72%	301.97%	98.13%	0.00%	16.09%
Net Working Capital to Revenue	20.42%	1,250.69%	4,227.99%	2,123.72%	301.97%	98.13%	0.00%	16.09%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	($1.64)	($1.08)	($1.49)	($0.59)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	0.00	0.00	34.88M	47.13M	47.43M	48.41M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($1.64)	($1.08)	($1.49)	($0.59)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	0.00	0.00	34.88M	47.13M	47.43M	48.41M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	0.00	34.88M	47.13M	47.43M	48.41M
Normalized Net Operating Profit after Tax (NOPAT)	-24	-37	-31	-42	-35	-21	-50	-8.89
Normalized NOPAT Margin	-604.97%	-1,288.68%	-1,015.14%	-1,390.45%	-684.49%	-51.77%	0.00%	-23.23%
Pre Tax Income Margin	-880.17%	-2,003.62%	-1,336.86%	-1,775.56%	-1,194.14%	-109.32%	0.00%	-73.51%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-20.94	-9.41	0.00	-67.41	-3.37	-1.81	-9.13	-0.71
NOPAT to Interest Expense	-14.53	-6.59	0.00	-47.19	-2.36	-1.27	-6.39	-0.50
EBIT Less CapEx to Interest Expense	-20.65	-9.70	0.00	-67.71	-3.38	-1.81	-9.25	-0.75
NOPAT Less CapEx to Interest Expense	-14.24	-6.88	0.00	-47.49	-2.36	-1.27	-6.51	-0.53
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-2.82%	-30.84%	-0.74%	0.00%	0.00%	0.00%	0.00%

No quarterly metrics and ratios for Nanobiotix are available.

Financials Breakdown Chart

Nanobiotix Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Nanobiotix's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Nanobiotix's net income were at -$28.12 million at the end of 2025, a 60.1% decrease from 2024, and a 19.0% decrease since 2018. See Nanobiotix's forecast for analyst expectations on what's next for the company.

Nanobiotix's total operating income in 2025 was -$12.70 million, based on the following breakdown:

Total Gross Profit: $38.25 million
Total Operating Expenses: $50.95 million

Over the last 7 years, Nanobiotix's total revenue changed from $3.98 million in 2018 to $38.25 million in 2025, a change of 860.7%.

Nanobiotix's total liabilities were at $178.67 million at the end of 2025, a 29.7% increase from 2024, and a 417.6% increase since 2018.

In the past 7 years, Nanobiotix's cash and equivalents has ranged from $0.00 in 2018 to $145.56 million in 2020, and is currently $61.91 million as of their latest financial filing in 2025.

Over the last 7 years, Nanobiotix's book value per share changed from 0.00 in 2018 to -9.28 in 2025, a change of -927.8%.

Related Companies

Financial statements for NASDAQ:NBTX last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanobiotix (NBTX) Financials

Financials Breakdown Chart

Nanobiotix Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nanobiotix (NBTX) Financials

Annual Income Statements for Nanobiotix

Quarterly Income Statements for Nanobiotix

Annual Cash Flow Statements for Nanobiotix

Quarterly Cash Flow Statements for Nanobiotix

Annual Balance Sheets for Nanobiotix

Quarterly Balance Sheets for Nanobiotix

Annual Metrics And Ratios for Nanobiotix

Quarterly Metrics And Ratios for Nanobiotix

Financials Breakdown Chart

Nanobiotix Financials - Frequently Asked Questions

When does Nanobiotix's fiscal year end?

How has Nanobiotix's net income changed over the last 7 years?

What is Nanobiotix's operating income?

How has Nanobiotix's revenue changed over the last 7 years?

How much debt does Nanobiotix have?

How much cash does Nanobiotix have?

How has Nanobiotix's book value per share changed over the last 7 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools